RESUMEN
Objective: To observe the effect of Mirabilis Jalapa seeds on Liver function tests of Rabbit
Study Design: Experimental study
Place and Duration of Study: This study was carried out in the Department of Pharmacology and Therapeutics, Baqai Medical College/ University for a period of 2 months from 1.10.2011 to 30.11.2011
Materials and Methods: For this study twenty seven rabbits of either sex were selected and divided in three groups, control group, low dose group and high dose group, each group having nine rabbits. The dose of the drug was calculated according to weight of the animals
Results: The liver function tests [LFT] were done after 60 days administration of mirabilis jalapa seeds. Total serum bilirubin in control group was 0.69 +/- 0.03, in low dose group 0.71 +/- 0.03 and in high dose group 0.73 +/- 0.03 with P value 0.197. Direct serum bilirubin was 0.34 +/- 0.02; 0.34 +/- 0.03; 0.31 +/- 0.03 with P value 0.687 in control group, low dose group and in high dose group respectively. Indirect serum bilirubin was 0.35 +/- 0.01 [control group]; 0.37 +/- 0.03 [low dose group] but in high dose group it decreased to 0.32 +/- 0.02 with P value 0.409. SGPT in control group was 78.7 +/- 3.01; in low dose group it was 74.1 +/- 2.08 and in high dose it was 100.0 +/- 2.08 with P value 0.001. Serum alkaline phosphate [IU/ L] was 44.4 +/- 1.53 with low dose it was 26.1 +/- 1.14 with high dose it was 114.6 +/- 1.14 with P value 0.001
Conclusions: Mirabilis Jalapa seems to be useful drug and further studies regarding its use are recommended
RESUMEN
Objective: the objective of this study was to identify the risk factors in NSAID users
Study design and setting: comparative prospective study, performed at the Department of Pharmacology and Therapeutics BMSI, JPMC with the collaboration of Departments of Medicine and Rheumatology JPMC Karachi from February 2008 to August 2008
Materials and methods: this study was performed on endoscopically diagnosed patients of NSAID induced peptic ulcers, in whom a clinical trial was performed between Ranitidine [H2 Receptor blocker] and new proton pump inhibitor Esomeprazole. Eighty Patients were selected and evaluated for presence of risk factors and dyspepsia after consumption of NSAIDs or low dose aspirin for last 6 months to 1 year. They were asked to fill in a specially designed proforma regarding the use of NSAIDs, which also included the questions for their social setup, habits and diseases for which they were taking them. All the patients were tested for presence of H. pylori infection and anti-H. Pylori IgG antibody titers were determined by enzyme-linked immunosorbent assay. Patients taking anticoagulants and steroids were excluded from the study
Results: important factors that have been shown to increase the risk of NSAID-associated GI complications in our study included female gender [76%] presence of H.pylori infection [71%], combination of two NSAIDs [23.75%] and high-dose NSAID use [20%]. Other factors that may increase risk include social habits like heavy consumption of tea [30%], pan or Gutka consumption [8.75%]. Current evidence supports that H. pylorus potentates the risk of NSAID-induced gastrointestinal ulcers or clinical events, and a strategy of H. pylori testing and treatment in NSAID users may be adopted
Conclusions: the incidence of NSAID related gastrointestinal problems was present in 10- 15% of patients who belonged to high risk group. Identifying them is strongly recommended to avoid serious complications. H. pylori infection may also be eradicated before initiating NSAID therapy